DelveInsightの分析によると、非嚢胞性線維症性気管支拡張症市場は2034年まで大幅な拡大が見込まれています | Insmed

DelveInsight has released a comprehensive report titled "Non-Cystic Fibrosis Bronchiectasis Market Insights, Epidemiology, and Market Forecast-2034" providing detailed analysis of Non-Cystic Fibrosis Bronchiectasis, including historical and projected epidemiological data as well as market trends across the United States, EU4 nations (Germany, Spain, Italy, France), the United Kingdom, and Japan.

For detailed information regarding the Non-Cystic Fibrosis Bronchiectasis market projections, medication adoption patterns, treatment landscape, and epidemiological trends, visit: Non-Cystic Fibrosis Bronchiectasis Market Forecast https://www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-market?utm_source=apac&utm_medium=promotion&utm_campaign=kkpr

Essential Highlights from the Non-Cystic Fibrosis Bronchiectasis Market Analysis

• The Non-Cystic Fibrosis Bronchiectasis market was valued at approximately USD 1,725 million in 2023 and is projected to expand at a substantial CAGR throughout the study period (2020-2034)
• In April 2025, Brensocatib showed substantial reduction in the annual rate of pulmonary exacerbations and decline in respiratory function versus placebo in patients with non-cystic fibrosis bronchiectasis, according to Phase III ASPEN trial (NCT04594369) findings published in The New England Journal of Medicine (NEJM). This persistent and progressive disease is characterized by recurring exacerbations, declining respiratory function, and reduced life quality, elevating the risk of premature death from multiple causes. Based on the favorable outcomes from the ASPEN trial, the FDA awarded Priority Review designation to the New Drug Application (NDA) for brensocatib in this patient population in February.
• In February 2025, The FDA awarded Priority Review designation to brensocatib, an investigational treatment for patients with non-cystic fibrosis bronchiectasis. Following the acceptance of the New Drug Application (NDA), a target decision date has been established for August 12, 2025. Upon approval, brensocatib would represent the first and only sanctioned treatment specifically indicated for bronchiectasis. Furthermore, it would mark the inaugural approval in a novel therapeutic category—dipeptidyl peptidase 1 (DPP1) inhibitors—developed to treat neutrophil-mediated conditions. This regulatory achievement highlights the potential importance of brensocatib in fulfilling a substantial unmet medical requirement in respiratory medicine.
• In February 2025, Verona Pharma operated as a biopharmaceutical enterprise dedicated to developing and marketing innovative treatments for chronic respiratory disorders with considerable unmet requirements. Its inaugural commercial offering, OhtuvayreTM (ensifentrine), is an innovative inhaled therapy for COPD maintenance that distinctively provides both bronchodilator and non-steroidal anti-inflammatory properties within a single molecule. Ensifentrine also demonstrates potential for treating additional respiratory disorders, including non-cystic fibrosis bronchiectasis, cystic fibrosis, asthma, and others.
• In December 2024, Armata Pharmaceuticals, Inc. (NYSE American: ARMP), a biotechnology enterprise specializing in high-purity, targeted bacteriophage treatments for chronic respiratory diseases and antibiotic-resistant infections, announced encouraging preliminary findings from its Phase 2 "Tailwind" clinical study. This investigation is assessing AP-PA02, an innovative inhaled multi-phage treatment developed to address chronic Pseudomonas aeruginosa infections in people with non-cystic fibrosis bronchiectasis (NCFB).
• In July 2024, Armata Pharmaceuticals announced the completion of participant enrollment for its Phase II Tailwind clinical study, which is evaluating the effectiveness of inhaled AP-PA02 in people with non-cystic fibrosis bronchiectasis (NCFB) and chronic Pseudomonas aeruginosa infection.
• The combined market value for the EU4 and the UK was calculated at approximately USD 524 million in 2023.
• In 2023, the market value for NCFB in the US was calculated at approximately USD 762 million and is projected to expand throughout the forecast timeframe.
• DelveInsight's calculations indicate that, within the EU4 and the UK, the UK had the greatest market value in 2023 at roughly USD 196 million, followed by Spain with approximately USD 151 million, and Italy at USD 90 million for the identical year.
• In 2023, Japan's aggregate market value for NCFB was roughly USD 439 million, representing nearly 25% of the total market revenue throughout the 7MM.
• DelveInsight's epidemiological model calculated approximately 1.4 million diagnosed prevalent cases of Non-Cystic Fibrosis Bronchiectasis in the 7MM in 2023. This figure is anticipated to increase over the forecast timeframe (2024-2034) owing to increasing awareness and improvements in diagnostic methodologies.
• In 2023, the United States had roughly 371,000 diagnosed prevalent cases of Non-Cystic Fibrosis Bronchiectasis, representing about 27% of the aggregate cases in the 7MM.
• In the US, the count of females diagnosed with NCFB exceeds that of males. In 2023, females accounted for approximately 244,000 cases, versus roughly 127,000 cases in males. These numbers are anticipated to grow throughout the study timeframe (2020-2034).
• In the EU4 and the UK, the frequency of moderate Non-Cystic Fibrosis Bronchiectasis (NCFB) cases is the greatest, followed by mild and severe cases. In 2023, there were approximately 198,000 moderate, 153,000 mild, and 143,000 severe NCFB cases, with these figures expected to increase throughout the forecast timeframe.
• In 2023, Japan had roughly 98,000 NCFB cases associated with post-infection, 5,000 to COPD, 7,000 to immunodeficiency, 6,000 to asthma, 206,000 to other causes, and 166,000 cases with unknown or idiopathic origins.
• In 2023, calculations indicate that Japan reported approximately 132,000 cases of Pseudomonas aeruginosa, 112,000 cases of Haemophilus influenzae, 39,000 cases of Streptococcus pneumoniae, 97,000 cases classified as other pathogens, and 107,000 cases with no growth in the microbiology of NCFB patients.
• Leading Non-Cystic Fibrosis Bronchiectasis Companies: Boehringer Ingelheim, Zambon, Insmed, AstraZeneca, Zambion, The Marcus Foundation, Inc., Chiesi Farmaceutici S.p.A., SolAeroMed Inc., Zambon SpA, Boehringer Ingelheim, Renovion, Inc., Novartis, Alaxia SAS, and others
• Notable Non-Cystic Fibrosis Bronchiectasis Therapies: CMS I-neb, BI 1291583, Brensocatib, Colistimethatesodium, Trikafta, CHF 6333, S-1226, CMS, BI 1323495, ARINA-1, TIP, ALX-009, and others
• The Non-Cystic Fibrosis Bronchiectasis epidemiological data based on gender demonstrated that in the US, females diagnosed with NCFB exceed males in number.
• The Non-Cystic Fibrosis Bronchiectasis market is anticipated to expand owing to the disease's growing prevalence and awareness throughout the forecast period. Moreover, introducing multiple pipeline products at various developmental stages will substantially transform the Non-Cystic Fibrosis Bronchiectasis market dynamics.

Understanding Non-Cystic Fibrosis Bronchiectasis

Non-cystic fibrosis bronchiectasis (NCFB) represents a chronic respiratory disorder distinguished by the irregular dilation and inflammation of the bronchial airways in the lungs. Unlike cystic fibrosis (CF)-related bronchiectasis, which results from genetic mutations impacting mucus production, NCFB develops in people without CF.

Access a complimentary sample for the Non-Cystic Fibrosis Bronchiectasis Market Forecast, Size & Share Analysis Report.

https://www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-market?utm_source=apac&utm_medium=promotion&utm_campaign=kkpr

Non-Cystic Fibrosis Bronchiectasis Patient Demographics

The epidemiology section delivers insights into the historical, current, and projected epidemiological patterns in the seven major countries (7MM) from 2020 to 2034. It facilitates recognition of the factors behind current and forecasted patterns by examining multiple studies and perspectives of key opinion leaders. The epidemiology section also furnishes a comprehensive analysis of the diagnosed patient population and future patterns.

Non-Cystic Fibrosis Bronchiectasis Epidemiological Breakdown:

The Non-Cystic Fibrosis Bronchiectasis market report presents epidemiological analysis for the study timeframe 2020-2034 in the 7MM divided into:

• Total Prevalence of Non-Cystic Fibrosis Bronchiectasis
• Prevalent Cases of Non-Cystic Fibrosis Bronchiectasis by severity
• Gender-specific Prevalence of Non-Cystic Fibrosis Bronchiectasis
• Diagnosed Cases of Episodic and Chronic Non-Cystic Fibrosis Bronchiectasis

Download the report to comprehend which factors are influencing Non-Cystic Fibrosis Bronchiectasis epidemiological trends @ Non-Cystic Fibrosis Bronchiectasis Epidemiology Forecast https://www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-market?utm_source=apac&utm_medium=promotion&utm_campaign=kkpr

Non-Cystic Fibrosis Bronchiectasis Medication Adoption and Pipeline Development Activities

The medication adoption section concentrates on the uptake rate of potential medications recently introduced in the Non-Cystic Fibrosis Bronchiectasis market or anticipated to launch during the study timeframe. The analysis encompasses Non-Cystic Fibrosis Bronchiectasis market adoption by medications, patient adoption by treatments, and revenue of each medication.

Furthermore, the therapeutics evaluation section facilitates understanding of the medications with the most accelerated adoption and the rationale behind the maximum utilization of the medications. Additionally, it contrasts the medications based on market share.

The report also addresses the Non-Cystic Fibrosis Bronchiectasis Pipeline Development Activities. It delivers valuable insights about different therapeutic candidates in multiple stages and the leading companies engaged in developing targeted treatments. It also examines recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging treatments.

Non-Cystic Fibrosis Bronchiectasis Treatments and Leading Companies

• CMS I-neb: Zambon
• BI 1291583: Boehringer Ingelheim
• Brensocatib: Insmed/ AstraZeneca
• Colistimethatesodium: Zambion
• Trikafta: The Marcus Foundation, Inc.
• CHF 6333: Chiesi Farmaceutici S.p.A.
• S-1226: SolAeroMed Inc.
• CMS: Zambon SpA
• BI 1323495: Boehringer Ingelheim
• ARINA-1: Renovion, Inc.
• TIP: Novartis
• ALX-009: Alaxia SAS

Explore more about treatments positioned to capture significant Non-Cystic Fibrosis Bronchiectasis market share @ Non-Cystic Fibrosis Bronchiectasis Treatment Landscape https://www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-market?utm_source=apac&utm_medium=promotion&utm_campaign=kkpr

Based on comprehensive research of clinical trial activity in Non-Cystic Fibrosis Bronchiectasis, there are currently no Japanese, Korean, or Taiwanese companies acting as primary sponsors or co-sponsors of NCFB clinical trials from Phase 1 through Phase 3. Despite extensive searches across clinical trial registries, pharmaceutical industry reports, and recent publications, Japan has no pharmaceutical or biotechnology companies currently sponsoring NCFB clinical trials, although Japanese patients have participated in multinational trials such as the ASPEN trial for brensocatib sponsored by Insmed. While South Korea has emerged as a significant hub for clinical trials globally, ranking fourth in clinical trial hubs with Seoul ranking first as a clinical trial city, no Korean companies are sponsoring NCFB-specific drug development programs, though Korean sites participate in multinational trials sponsored by Western companies. Similarly, no Taiwanese companies were identified as sponsors of NCFB clinical trials, and Taiwan was notably excluded from the China Bronchiectasis Registry (BE-China, NCT03643653), which enrolled medical centers from Hong Kong and Macau but not Taiwan.

However, Haisco Pharmaceutical Group Co., Ltd., a Chinese company headquartered in Chengdu, represents the only major Asian pharmaceutical company with a comprehensive NCFB drug development program spanning Phase 1 through Phase 3 trials. Haisco is developing HSK31858, a novel, oral, selective, reversible dipeptidyl peptidase-1 (DPP1) inhibitor that works by inhibiting DPP1, which is responsible for activating neutrophil serine proteases (NSPs) such as neutrophil elastase in neutrophils during bone marrow formation. By inhibiting DPP1, it reduces NSP activity and neutrophilic inflammation without affecting neutrophil bactericidal functions. HSK31858 has completed Phase 1 trials in Australia (NCT05023525) and China (NCT05663593), as well as a Phase 2 trial (NCT05601778 - SAVE-BE trial). In March 2025, Phase 2 SAVE-BE trial results published in The Lancet Respiratory Medicine showed HSK31858 at both 20mg and 40mg doses significantly reduced annualized exacerbation frequency compared to placebo, with the 20mg dose showing an incidence rate ratio of 0.52 (p=0.0031) and the 40mg dose showing 0.41 (p=0.0002) compared to placebo. The drug demonstrated a favorable safety profile with no new signals of life-threatening infections or neutropenia in completed trials. In November 2023, Chiesi Farmaceutici S.p.A. from Italy signed an exclusive licensing agreement with Haisco to develop, manufacture, and commercialize HSK31858 outside Greater China, excluding Hong Kong SAR, Macau SAR, and Taiwan, with Chiesi making upfront payments, milestone payments, and royalties on product sales. A Phase 3 trial (NCT06660992) is currently enrolling an estimated 669 participants across China to assess efficacy and safety over 52 weeks. All other active Phase 2 and Phase 3 NCFB clinical trials are sponsored by Western pharmaceutical companies including Insmed, AstraZeneca, Boehringer Ingelheim, Zambon, Verona Pharma, Sanofi/Regeneron, and Armata Pharmaceuticals.

Non-Cystic Fibrosis Bronchiectasis Market Advantages

• Growing disease prevalence owing to enhanced detection rate with advanced imaging methodologies and improved awareness.
• An enhanced comprehension of disease pathophysiology has improved diagnosis and is valuable in identifying novel target molecules for treatment development.

Non-Cystic Fibrosis Bronchiectasis Market Possibilities

• Large, favorable, randomized controlled studies are essential to establish the standard of care for bronchiectasis patients.
• Vaccines and monoclonal antibodies, though partially beneficial, there is a requirement for evidence-based investigations to utilize for the prevention of PA chronic colonization in bronchiectasis patients.

Coverage of the Non-Cystic Fibrosis Bronchiectasis Market Report

• Study Timeframe: 2020-2034
• Geographic Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Leading Non-Cystic Fibrosis Bronchiectasis Companies: Boehringer Ingelheim, Zambon, Insmed, AstraZeneca, Zambion, The Marcus Foundation, Inc., Chiesi Farmaceutici S.p.A., SolAeroMed Inc., Zambon SpA, Boehringer Ingelheim, Renovion, Inc., Novartis, Alaxia SAS, and others
• Notable Non-Cystic Fibrosis Bronchiectasis Therapies: CMS I-neb, BI 1291583, Brensocatib, Colistimethatesodium, Trikafta, CHF 6333, S-1226, CMS, BI 1323495, ARINA-1, TIP, ALX-009, and others
• Non-Cystic Fibrosis Bronchiectasis Therapeutic Evaluation: Non-Cystic Fibrosis Bronchiectasis current marketed and Non-Cystic Fibrosis Bronchiectasis emerging treatments
• Non-Cystic Fibrosis Bronchiectasis Market Dynamics: Non-Cystic Fibrosis Bronchiectasis market drivers and Non-Cystic Fibrosis Bronchiectasis market obstacles
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Non-Cystic Fibrosis Bronchiectasis Unmet Requirements, KOL's perspectives, Analyst's perspectives, Non-Cystic Fibrosis Bronchiectasis Market Access and Reimbursement

To learn more about Non-Cystic Fibrosis Bronchiectasis companies operating in the treatment market, visit @ Non-Cystic Fibrosis Bronchiectasis Clinical Trials and Therapeutic Assessment https://www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-market?utm_source=apac&utm_medium=promotion&utm_campaign=kkpr

Report Contents

1. Non-Cystic Fibrosis Bronchiectasis Market Report Introduction
2. Executive Summary for Non-Cystic Fibrosis Bronchiectasis
3. SWOT analysis of Non-Cystic Fibrosis Bronchiectasis
4. Non-Cystic Fibrosis Bronchiectasis Patient Share (%) Overview at a Glance
5. Non-Cystic Fibrosis Bronchiectasis Market Overview at a Glance
6. Non-Cystic Fibrosis Bronchiectasis Disease Background and Overview
7. Non-Cystic Fibrosis Bronchiectasis Epidemiology and Patient Population
8. Country-Specific Patient Population of Non-Cystic Fibrosis Bronchiectasis
9. Non-Cystic Fibrosis Bronchiectasis Current Treatment and Medical Practices
10. Non-Cystic Fibrosis Bronchiectasis Unmet Needs
11. Non-Cystic Fibrosis Bronchiectasis Emerging Therapies
12. Non-Cystic Fibrosis Bronchiectasis Market Outlook
13. Country-Wise Non-Cystic Fibrosis Bronchiectasis Market Analysis (2020-2034)
14. Non-Cystic Fibrosis Bronchiectasis Market Access and Reimbursement of Therapies
15. Non-Cystic Fibrosis Bronchiectasis Market Drivers
16. Non-Cystic Fibrosis Bronchiectasis Market Barriers
17. Non-Cystic Fibrosis Bronchiectasis Appendix
18. Non-Cystic Fibrosis Bronchiectasis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About DelveInsight

DelveInsight operates as a premier healthcare-focused market research and consulting organization, delivering superior market intelligence and analysis to clients that enable informed business decisions. With a team of seasoned industry specialists and an extensive understanding of the life sciences and healthcare industries, we provide tailored research solutions and insights to clients throughout the world. Partner with us to obtain high-quality, precise, and current intelligence to remain ahead of the growth trajectory.

Related Reports:

Non-Cystic Fibrosis Bronchiectasis Pipeline-https://www.delveinsight.com/report-store/non-cystic-fibrosis-bronchiectasis-ncfb-pipeline-insight?utm_source=apac&utm_medium=promotion&utm_campaign=kkpr

"Non-Cystic Fibrosis Bronchiectasis Pipeline Insight, 2025" report by DelveInsight presents comprehensive insights of present clinical development scenarios and growth prospects throughout the Non-Cystic Fibrosis Bronchiectasis market. A comprehensive picture of the Non-Cystic Fibrosis Bronchiectasis pipeline landscape is presented, which includes the disease overview and Non-Cystic Fibrosis Bronchiectasis treatment guidelines.

Non-Cystic Fibrosis Bronchiectasis Epidemiology-https://www.delveinsight.com/report-store/non-cystic-fibrosis-bronchiectasis-epidemiology-forecast?utm_source=apac&utm_medium=promotion&utm_campaign=kkpr

DelveInsight's 'Non-Cystic Fibrosis Bronchiectasis Epidemiology Forecast to 2034' report provides an in-depth comprehension of the disease, historical and forecasted Non-Cystic Fibrosis Bronchiectasis epidemiology in the 7MM, specifically, the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Media Contact

Company Name: DelveInsight Business Research LLP

Contact Person: Kanishk Kumar

Email: kkumar@delveinsight.com 

Phone: 09650213330

Address: 304 S. Jones Blvd #2432

City: Las Vegas

State: NV

Country: United States

Website: https://www.delveinsight.com/